$OBMP is a small biotech player we have covered a
Post# of 53474
This is the big news the company was waiting for, and should put them on the prostate cancer pipeline game board, along with key players such as Seattle Genetics, Inc. (NASDAQ:SGEN), Inovio Pharmaceuticals (NASDAQ:INO), Nymox Pharmaceutical Corporation (NASDAQ:NYMX). The key news came from the Department of Urology of the High Specialty Hospital IMSS Siglo XXI in Mexico. In the study, ProscaVax, OncBioMune’s lead experimental therapeutic cancer vaccine, will be evaluated for safety and efficacy in prostate specific antigen (PSA) recurrent prostate cancer in hormone-naïve and hormone-independent patients.
https://www.journaltranscript.com/2017/01/onc...s-surging/